Related Experiment Video
Updated: Mar 8, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Muthiah Vaduganathan1, Robert A Harrington2, Gregg W Stone3
1Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts.
Insights
Cangrelor effectively reduces ischemic complications in patients undergoing percutaneous coronary intervention (PCI), regardless of glycoprotein IIb/IIIa inhibitor (GPI) use. However, GPI administration significantly increases bleeding risk in both cangrelor and clopidogrel groups.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Cangrelor is an approved intravenous P2Y12 antagonist for percutaneous coronary intervention (PCI).
- Glycoprotein IIb/IIIa inhibitors (GPIs) are also used in PCI, but their interaction with P2Y12 antagonists requires further investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of cangrelor compared to clopidogrel.
- To analyze outcomes in patients who received or did not receive GPIs during PCI.
Main Methods:
- A pooled patient-level analysis of 3 CHAMPION trials involving 24,902 patients undergoing PCI.
- Comparison of cangrelor versus clopidogrel, with subgroup analysis based on GPI use (bailout/rescue or routine).
- Primary efficacy endpoint: composite of mortality, myocardial infarction, revascularization, or stent thrombosis within 48 hours.
Main Results:
- Cangrelor demonstrated lower rates of the primary composite endpoint compared to clopidogrel, both in patients who received GPIs (4.9% vs. 6.5%) and those who did not (3.6% vs. 4.4%).
- Cangrelor did not increase the risk of severe/life-threatening bleeding, irrespective of GPI use.
- GPI use was associated with significantly higher bleeding rates in both treatment arms.
Conclusions:
- Cangrelor's efficacy in reducing ischemic events during PCI is consistent, regardless of concomitant GPI administration.
- GPI use is linked to increased bleeding risk, independent of whether cangrelor or clopidogrel is administered.
- These findings support cangrelor's role in PCI, highlighting the importance of careful GPI consideration due to bleeding risks.
Background:
Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous coronary intervention (PCI).
Objectives:
This study sought to evaluate the efficacy and safety of cangrelor compared with clopidogrel in subgroups that did and did not receive glycoprotein IIb/IIIa inhibitors (GPIs).
Methods:
This pooled, patient-level analysis of the 3 CHAMPION (Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) trials analyzed all randomized patients who underwent PCI and received the study drug (n = 24,902). Only bailout/rescue GPI use was permitted, except in CHAMPION PCI, in which routine or bailout/rescue GPI use was at the site investigator's discretion. The primary efficacy endpoint was the composite of all-cause mortality, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 h after randomization.
Results:
Overall, 3,173 patients (12.7%) received a GPI, most commonly eptifibatide (69.4%). Despite variation in indications for GPIs, baseline characteristics were well balanced between the cangrelor and clopidogrel arms in subsets receiving and not receiving GPIs. Rates of the primary composite endpoint were lower with cangrelor compared with clopidogrel in patients who did (4.9% vs. 6.5%; odds ratio [OR]: 0.74; 95% confidence interval [CI]: 0.55 to 1.01) or did not receive a GPI (3.6% vs. 4.4%; OR: 0.82; 95% CI: 0.72 to 0.94; Pint = 0.55). Cangrelor did not increase the primary safety endpoint, GUSTO-defined severe/life-threatening bleeding, in patients who did (0.4% vs. 0.5%; OR: 0.71; 95% CI: 0.25 to 1.99) or did not receive GPIs (0.2% vs. 0.1%; OR: 1.56; 95% CI: 0.80 to 3.04; Pint = 0.21). GPI use was associated with increased risk of bleeding in both treatment arms.
Conclusions:
Cangrelor's efficacy in reducing ischemic complications in patients undergoing PCI was maintained irrespective of GPI administration. GPI use was associated with substantially higher bleeding rates, regardless of the randomization to cangrelor or clopidogrel. (A Clinical Trial to Demonstrate the Efficacy of Cangrelor [PCI]: NCT00305162; Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition [PLATFORM]: NCT00385138; A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI] [CHAMPION PHOENIX] [CHAMPION]: NCT01156571).
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Angina IV: Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Acute Coronary Syndrome IV: Interprofessional Care